Medicare expands obesity treatment access for 27 million seniors

What it does

This bill expands Medicare coverage for obesity treatment by allowing a broader range of health care providers—including physician assistants, nurse practitioners, dietitians, clinical psychologists, and community-based lifestyle programs—to deliver intensive behavioral therapy for obesity, and requires Medicare Part D drug plans to cover FDA-approved obesity medications (like GLP-1 agonists) starting two years after enactment. The bill aims to reduce the $50 billion annual Medicare spending on obesity-related care by making treatment more accessible and comprehensive.

Why we flagged it

The bill's core mechanism is expanding Medicare coverage for obesity treatment—a public health intervention addressing a documented epidemic. While pharmaceutical companies manufacturing obesity medications stand to benefit financially, the primary driver is broadening access to care for seniors, not creating a private carve-out.

What the text implies

• Obesity medication coverage begins 2 years post-enactment, creating a lag during which pharmaceutical manufacturers may anticipate demand surge and adjust production/pricing strategies.
• Expansion of non-physician providers (PAs, NPs, dietitians, psychologists) may shift treatment delivery away from primary care physicians, potentially fragmenting care coordination despite the bill's coordination language.
• Community-based lifestyle programs approved by the Secretary gain federal funding pathway; the criteria for 'approval' are not specified in the bill, creating discretionary authority that could favor certain program models.
• The bill requires coordination between providers and referring physicians but does not establish enforcement mechanisms or penalties for non-compliance, potentially weakening the collaborative intent.
• Medicare Part D plans will bear the cost of obesity medications; plans may respond by raising premiums, imposing higher cost-sharing, or restricting formulary access to manage costs.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries gain expanded access to obesity treatment through more providers and newly covered medications, addressing a documented public health crisis affecting 41% of seniors and costing $50 billion annually. The bill removes barriers to care without imposing new costs on beneficiaries or restricting existing protections.

Who stands to gain

• Pharmaceutical manufacturers (obesity medications: GLP-1 agonists, others)
• Physician assistants, nurse practitioners, clinical psychologists, registered dietitians (expanded b
• Community-based lifestyle counseling programs (newly eligible for Medicare reimbursement)
• Medicare Part D insurers (initially bear medication costs; may offset via premium/cost-sharing adjus

Named in the bill

Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), Medicare (Title XVIII, Social Security Act), Medicare Part D, Secretary of Health and Human Services, FDA, Physician assistants, Nurse practitioners, Clinical psychologists, Registered dietitians, GLP-1 agonists (implied obesity medications)

Where it stands

85 cosponsors: 65 Democrats, 20 Republicans.

• Jun 27, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jun 27, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

9 lobbying clients named this bill on 14 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $5,024,615 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 89% of bills with at least one filing.

Mike Kelly, the sponsor, reported $955,974 in PAC receipts in the 2026 cycle.

• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
• Association of American Railroads — $1,260,000 on 1 filing
• Academy of Nutrition and Dietetics (formerly As American Dietetic Association) — $154,615 on 1 filing
• National Kidney Foundation — $140,000 on 2 filings
• Novo Nordisk, Inc. — $140,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.